用一种新型氟-18标记的选择性FABP3配体点亮心脏型脂肪酸结合蛋白(FABP3)
本研究将选择性FABP3抑制剂LUF经铜介导18F-氟化及碱性水解进行放射性标记,成功自动化合成[18F]LUF(活度14.0±1.8 GBq,摩尔活度>250 GBq/µmol,放化纯度>99.6%)。小动物PET显示[18F]LUF清晰显影心肌,绝对心肌摄取与[18F]flurpiridaz相当,并可显影永久性心肌梗死和实验性自身免疫性心肌炎病灶。
要点
- [18F]LUF自动化合成活度14.0±1.8 GBq,摩尔活度>250 GBq/µmol,放化纯度>99.6%。
- [18F]LUF清晰显影心肌,高对比于肺和肝,绝对心肌摄取与[18F]flurpiridaz相当。
- [18F]LUF成功显影大鼠永久性心肌梗死和实验性自身免疫性心肌炎病灶。
核心结论
- 首次显示18F标记的FABP3选择性小有机化合物可清晰、高质量地显影心肌。
- 为确定[18F]LUF在临床实践中的心血管疾病临床用途,需评估更多种类的心血管疾病模型并阐明蓄积机制,尤其与心肌脂肪酸代谢的关系。
研究设计与样本
- 本研究为放射性药物合成与生物学评价的临床前研究,包括自动化放射合成、体内生物分布、代谢物分析及小动物PET成像。
- 研究进行了大鼠外科永久性心肌梗死(MI)和实验性自身免疫性心肌炎(EAM)的PET成像。
主要发现
- [18F]LUF经两步反应自动化合成,活度为14.0±1.8 GBq,摩尔活度>250 GBq/µmol,放化纯度>99.6%。
- [18F]LUF清晰显影心肌,与肺、肝等背景组织对比度高。
- [18F]LUF的绝对心肌摄取与有前景的心肌灌注示踪剂[18F]flurpiridaz相当,且在体内代谢稳定性优异。
- [18F]LUF成功显影大鼠永久性心肌梗死和实验性自身免疫性心肌炎病灶。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 为确定[18F]LUF在临床实践中的心血管疾病临床用途,需评估更多种类的心血管疾病模型并阐明蓄积机制,尤其与心肌脂肪酸代谢的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart-type fatty acid binding proteins (FABP3) constitute a family of lipid chaperone proteins. They are found in the cytosol and enhance cellular fatty acid solubilisation, transport, and metabolism. FABP3 is highly expressed in the myocardium and is released from myocytes during myocardial damage. As FABP3 content in the myocardium is closely related to the metabolic state of fatty acids, we hypothesised that targeting of FABP3 with a radiolabelled small organic compound would visualise myocardium. RESULTS: The selective FABP3 inhibitor, 4-(4-fluoro-2-(1-phenyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)phenoxy)butanoic acid (LUF), was radiolabelled via a two-step reaction comprising copper-mediated 18F-fluorination of an arylboronic precursor followed by alkaline hydrolysis of the ethoxy protecting group. [18F]LUF was successfully synthesised by automated synthesiser with sufficient activity yields (14.0 ± 1.8 GBq) and high quality (molar activity, > 250 GBq/µmol and radiochemical purity, > 99.6%). Biological assessment of [18F]LUF as an in vivo myocardial imaging agent included evaluations of biodistribution, metabolite analysis, and positron emission tomography (PET) imaging of small animals. [18F]LUF clearly visualised the myocardium with high contrast against background tissues such as the lung and liver. [18F]LUF also showed a high absolute myocardial uptake equivalent to that of the promising myocardial perfusion tracer [18F]flurpiridaz and excellent metabolic stability in the body. These properties are ideal for stable and noise-less imaging of the heart. PET imaging of rat surgical permanent myocardial infarction (MI) and experimental autoimmune myocarditis (EAM) was also performed. [18F]LUF successfully visualised lesions of permanent MI and EAM. CONCLUSION: Our results showed for the first time that the 18F-labelled FABP3 selective small organic compound clearly visualised myocardium with good quality. To determine the clinical utility of [18F]LUF for cardiovascular disease in clinical practice, it will be necessary to evaluate a greater variety of cardiovascular disease models and elucidate the accumulation mechanism, particularly in relation to fatty acid metabolism in the myocardium.
引用
- Toyohara J, Komoda T, Tago T, et al. Light up heart-type fatty acid binding protein (FABP3) with a novel fluorine-18 labelled selective FABP3 ligand. EJNMMI Res. 2024. PMID: 39542944. doi:10.1186/s13550-024-01175-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。